Navigation Links
Gene Network Sciences Announces Michael Gilman as Board Member
Date:2/24/2009

CAMBRIDGE, Mass., Feb. 24 /PRNewswire/ -- Gene Network Sciences, Inc. (GNS) today announced that it has named Michael Gilman, Ph.D., Founder and Chief Executive Officer of Stromedix, Inc. and former Executive Vice President of Research at Biogen Idec, to its Board of Directors.

Dr. Gilman has been Founder and Chief Executive Officer of Stromedix since June 2006. He was previously Executive Vice President, Research at Biogen Idec. He joined Biogen in 1999 as Director of Molecular Biology and became head of research at Biogen in 2000. From 1994 to 1999, Dr. Gilman held several positions at ARIAD Pharmaceuticals, including Executive Vice President and Chief Scientific Officer. Prior to that, Dr. Gilman spent eight years on the scientific staff of Cold Spring Harbor Laboratory in New York, where his research focused on mechanisms of signal transduction and gene regulation. Dr. Gilman holds a Ph.D. in Biochemistry from University of California, Berkeley, and an S.B. in Life Sciences from Massachusetts Institute of Technology. He also serves on the Board of Directors of EPIX Pharmaceuticals, Inc.

"Michael Gilman's broad pharma research leadership experience will play a critical role in GNS's effectively deploying our REFS(TM) platform to accelerate pharma drug research and development," said Colin Hill, CEO of GNS. "I am looking forward to leveraging his experiences to create maximum impact for our partners."

"I was drawn to GNS by the power of the supercomputer-driven REFS(TM) platform to enable both new forms of discovery and new approaches to personalized medicine. The industry is at a crossroads, with advances in DNA sequencing finally paving the way to a more systematic exploration of disease biology and drug response markers. Data is no longer the bottleneck -- the analysis is. That's why I see technology such as GNS's as the missing link," said Dr. Gilman.

About Gene Network Sciences

Gene Network Sciences (http://www.gnsbiotech.com/) is a leader in biosimulation with its ability to derive molecular mechanisms of drugs and diseases directly from molecular profiling and clinical data. Based in Cambridge, Massachusetts, and Ithaca, New York, GNS uses its REFS(TM) technology in pharmaceutical and clinical settings to rapidly turn combinations of genetic, genomic, and clinical measurements into models of disease progression and drug response. These models are then simulated to discover both new targets for drug intervention and genetic markers of drug response that allow patients who will respond to a given drug treatment to be matched to a particular clinical trial. By discovering how and why specific sets of genes and drug candidates impact human biology, GNS technology enables the rapid development of breakthrough drug and diagnostic products.


'/>"/>
SOURCE Gene Network Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. UKs Institute of Cancer Research and Silicon Graphics Establish Long-Term Alliance to Design and Outfit World-Class Network Biology Lab
2. Yongye Biotechnology International to Expand its Network of Branded Stores
3. PAREXEL Establishes Alliance with SITS Network of Clinical Sites Specializing in Stroke Studies
4. BioFlorida Selects Collexis BiomedExperts.com as the Primary Professional Network for its 200 Member Companies and Organizations
5. HEALTHeCAREERS Network Pledges $15,000 to ASRT Foundation for Professional Healthcare Training
6. [video] Wall St. Networks 3-Minute Press Show Features Executive Interviews and Highlights Recent Press for the Following: GTHR, BHRT, AGO
7. OTC Financial Network Issues Corporate Profile on ProtoKinetix Inc.
8. GeoVaxs DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
9. [video] Wall St. Networks 3-Minute Press Show Features Executive Interviews and Highlights Recent Press for the Following: IMMU, KYUS
10. ProtoKinetix Partners with OTC Financial Network to Increase Shareholder Base
11. alli(TM) Partners with Breast Cancer Network of Strength(TM) to Support Women Challenged by Breast Cancer, Weight Loss or Both
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... RPS ... clinical study that demonstrates the accuracy of the FebriDx® test, a commercially-ready, ... acute bacterial and viral respiratory tract infections by testing the body’s immune ...
(Date:10/12/2017)... Diego, CA (PRWEB) , ... ... ... (https://www.onramp.bio/ ) has launched Rosalind™, the first-ever genomics analysis platform specifically ... all bioinformatics complexity. Named in honor of pioneering researcher Rosalind Franklin, who ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... Personal eye wash is a basic first ... eye at a time. So which eye do you rinse first if a dangerous substance ... Plum Duo Eye Wash with its unique dual eye piece. , “Whether its ...
(Date:10/11/2017)... -- VMS BioMarketing, a leading provider of patient support solutions, has ... (CNE) network, which will launch this week. The VMS CNEs ... professionals to enhance the patient care experience by delivering peer-to-peer ... care professionals to help women who have been diagnosed and ... ...
Breaking Biology Technology:
(Date:4/13/2017)... , April 13, 2017 UBM,s Advanced ... will feature emerging and evolving technology through ... Innovation Summits will run alongside the expo portion of ... sessions, panels and demonstrations focused on trending topics within ... advanced design and manufacturing event will take place June ...
(Date:4/11/2017)... -- NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" ... of independent Directors Mr. Robin D. Richards and ... furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer ... guidance and benefiting from their considerable expertise as we move ...
(Date:4/4/2017)...   EyeLock LLC , a leader of iris-based ... Patent and Trademark Office (USPTO) has issued U.S. Patent ... an iris image with a face image acquired in ... 45 th issued patent. "The ... the multi-modal biometric capabilities that have recently come to ...
Breaking Biology News(10 mins):